〔Abstract〕 Objective To observe the clinical efficacy of papaverine injection in the treatment of acute cerebral infarction. Methods A total of 86 patients with acute cerebral infarction admitted to Qingxi Hospital in Dongguan City from January 2019 to February 2020 were enrolled as the research subjects, and were randomly divided into two groups, the routine group and the papaverine group, with 43 cases in each group. The routine group was given Mailuoning injection and aspirin enteric-coated tablets for treatment, and the papaverine group was given Mailuoning injection, aspirin enteric-coated tablets combined with papaverine injection for treatment. Observe the improvement rate and neurological deficit score of the two groups [National Institutes of Health Stroke Scale (NIHSS) score]. Results After treatment, the excellent and good rate of patients in the papaverine group was 93.02%, which was higher than 76.74% in the conventional group. The difference was statistically significant (P < 0.05). After treatment, the NIHSS score (12.07 ± 2.15) of the papaverine group was lower than that of the conventional group (19.18 ± 3.74), and the difference was statistically significant (P < 0.05). Conclusion Papaverine injection has a significant clinical effect on acute cerebral infarction.